Promising approach
MyJourneywithCancer
Member Posts: 82
As I am waiting to read the full text, I would like to share this:
Next Generation Sequencing (NGS) is becoming a reliable approach for molecular profiling and treatment decision for non-small cell lung cancer (NSCLC) patients. At least one genetic alteration was found in 78% of the patients. 23% patients showed mutations for which approved (ALK, EGFR, ROS1) or emerging (BRAF, ERBB2, MET, RET) targeted therapies exist.
The details are here: https://www.ncbi.nlm.nih.gov/pubmed/29130105
Next Generation Sequencing (NGS) is becoming a reliable approach for molecular profiling and treatment decision for non-small cell lung cancer (NSCLC) patients. At least one genetic alteration was found in 78% of the patients. 23% patients showed mutations for which approved (ALK, EGFR, ROS1) or emerging (BRAF, ERBB2, MET, RET) targeted therapies exist.
The details are here: https://www.ncbi.nlm.nih.gov/pubmed/29130105
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 120.8K Cancer specific
- 2.8K Anal Cancer
- 440 Bladder Cancer
- 304 Bone Cancers
- 1.6K Brain Cancer
- 28.4K Breast Cancer
- 388 Childhood Cancers
- 27.8K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.8K Head and Neck Cancer
- 6.3K Kidney Cancer
- 660 Leukemia
- 779 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 232 Multiple Myeloma
- 7.1K Ovarian Cancer
- 47 Pancreatic Cancer
- 485 Peritoneal Cancer
- 5.2K Prostate Cancer
- 1.2K Rare and Other Cancers
- 531 Sarcoma
- 706 Skin Cancer
- 643 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Other Discussion Boards